Skip to main content
SpringerLink
Log in

Extended Surgery for Advanced Ovarian Cancer

  • Chapter
  • First Online:
Pelvic Cancer Surgery

  • 1958 Accesses

Abstract

Survival in women with advanced ovarian cancer has markedly improved over the last 30 years through the use of combination platinum and taxane as standard primary chemotherapy, and through progressive improvements in the ability to perform maximal cytoreductive surgery. The goal of surgical cytoreduction has evolved from residual disease ≤1 cm to no visible residual disease, supported by evidence that there is improved survival in women with no remaining visible disease. To achieve this goal, “extended surgery” beyond standard ovarian cancer cytoreduction, including increasingly radical pelvic resection and extensive upper abdominal procedures, are more frequently performed. This chapter details the rationale and procedures required to achieve maximal cytoreduction in most patients, as well as the available evidence for postoperative outcomes after extended surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  2. Ozols RF. Treatment goals in ovarian cancer. Int J Gynecol Cancer. 2005;15 Suppl 1:3–11.

    Article  PubMed  Google Scholar 

  3. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 1992;47(2):159–66.

    Article  CAS  PubMed  Google Scholar 

  4. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170(4):974–9; discussion 979–80.

    Article  CAS  PubMed  Google Scholar 

  5. Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003;90(2):390–6.

    Article  PubMed  Google Scholar 

  6. Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103(2):559–64.

    Article  CAS  PubMed  Google Scholar 

  7. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107(1):77–85.

    Article  PubMed  Google Scholar 

  8. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.

    Article  CAS  PubMed  Google Scholar 

  9. Winter 3rd WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(24):3621–7.

    Article  PubMed  Google Scholar 

  10. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115(6):1234–44.

    Article  PubMed  Google Scholar 

  11. Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, et al. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol. 2010;17(6):1642–8.

    Article  PubMed  Google Scholar 

  12. Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335(26):1950–5.

    Article  CAS  PubMed  Google Scholar 

  13. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(4):1001–7.

    CAS  PubMed  Google Scholar 

  14. Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining ‘optimal’ residual disease. Gynecol Oncol. 2012;125(2):483–92.

    Article  PubMed  Google Scholar 

  15. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006;103(3):1083–90.

    Article  PubMed  Google Scholar 

  16. Aletti GD, Podratz KC, Jones MB, Cliby WA. Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. J Am Coll Surg. 2006;203(4):521–6.

    Article  PubMed  Google Scholar 

  17. Ang C, Chan KK, Bryant A, Naik R, Dickinson HO. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011(4):CD007697.

    Google Scholar 

  18. Soper JT, Couchman G, Berchuck A, Clarke-Pearson D. The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma. Gynecol Oncol. 1991;41(3):239–44.

    Article  CAS  PubMed  Google Scholar 

  19. Scarabelli C, Gallo A, Franceschi S, Campagnutta E, De G, Giorda G, et al. Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer. 2000;88(2):389–97.

    Article  CAS  PubMed  Google Scholar 

  20. Obermair A, Hagenauer S, Tamandl D, Clayton RD, Nicklin JL, Perrin LC, et al. Safety and efficacy of low anterior en bloc resection as part of cytoreductive surgery for patients with ovarian cancer. Gynecol Oncol. 2001;83(1):115–20.

    Article  CAS  PubMed  Google Scholar 

  21. Clayton RD, Obermair A, Hammond IG, Leung YC, McCartney AJ. The Western Australian experience of the use of en bloc resection of ovarian cancer with concomitant rectosigmoid colectomy. Gynecol Oncol. 2002;84(1):53–7.

    Article  CAS  PubMed  Google Scholar 

  22. Bristow RE, del Carmen MG, Kaufman HS, Montz FJ. Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg. 2003;197(4):565–74.

    Article  PubMed  Google Scholar 

  23. Mourton SM, Temple LK, Abu-Rustum NR, Gemignani ML, Sonoda Y, Bochner BH, et al. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 2005;99(3):608–14.

    Article  PubMed  Google Scholar 

  24. Park JY, Seo SS, Kang S, Lee KB, Lim SY, Choi HS, et al. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Gynecol Oncol. 2006;103(3):977–84.

    Article  PubMed  Google Scholar 

  25. Houvenaeghel G, Gutowski M, Buttarelli M, Cuisenier J, Narducci F, Dalle C, et al. Modified posterior pelvic exenteration for ovarian cancer. Int J Gynecol Cancer. 2009;19(5):968–73.

    Article  PubMed  Google Scholar 

  26. Tixier H, Fraisse J, Chauffert B, Mayer F, Causeret S, Loustalot C, et al. Evaluation of pelvic posterior exenteration in the management of advanced-stage ovarian cancer. Arch Gynecol Obstet. 2010;281(3):505–10.

    Article  PubMed  Google Scholar 

  27. Gillette-Cloven N, Burger RA, Monk BJ, McMeekin DS, Vasilev S, DiSaia PJ, et al. Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer. J Am Coll Surg. 2001;193(6):626–32.

    Article  CAS  PubMed  Google Scholar 

  28. Hoffman MS, Griffin D, Tebes S, Cardosi RJ, Martino MA, Fiorica JV, et al. Sites of bowel resected to achieve optimal ovarian cancer cytoreduction: implications regarding surgical management. Am J Obstet Gynecol. 2005;193(2):582–6; discussion 586–8.

    Article  PubMed  Google Scholar 

  29. Estes JM, Leath 3rd CA, Straughn Jr JM, Rocconi RP, Kirby TO, Huh WK, et al. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy. J Am Coll Surg. 2006;203(4):527–32.

    Article  PubMed  Google Scholar 

  30. Bidzinski M, Derlatka P, Kubik P, Ziolkowska-Seta I, Danska-Bidzinska A, Gmyrek L, et al. The evaluation of intra- and postoperative complications related to debulking surgery with bowel resection in patients with FIGO stage III-IV ovarian cancer. Int J Gynecol Cancer. 2007;17(5):993–7.

    Article  CAS  PubMed  Google Scholar 

  31. Salani R, Zahurak ML, Santillan A, Giuntoli 2nd RL, Bristow RE. Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study. Gynecol Oncol. 2007;107(3):495–9.

    Article  PubMed  Google Scholar 

  32. Bristow RE, Peiretti M, Zanagnolo V, Salani R, Giuntoli 2nd RL, Maggioni A. Transverse colectomy in ovarian cancer surgical cytoreduction: operative technique and clinical outcome. Gynecol Oncol. 2008;109(3):364–9.

    Article  PubMed  Google Scholar 

  33. Silver DF, Bou Zgheib N. Extended left colon resections as part of complete cytoreduction for ovarian cancer: tips and considerations. Gynecol Oncol. 2009;114(3):427–30.

    Article  PubMed  Google Scholar 

  34. Song YJ, Lim MC, Kang S, Seo SS, Park JW, Choi HS, et al. Total colectomy as part of primary cytoreductive surgery in advanced Mullerian cancer. Gynecol Oncol. 2009;114(2):183–7.

    Article  PubMed  Google Scholar 

  35. Eisenkop SM, Spirtos NM. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol. 2001;82(3):489–97.

    Article  CAS  PubMed  Google Scholar 

  36. Eisenhauer EL, Chi DS. Liver mobilization and diaphragm peritonectomy/resection. Gynecol Oncol. 2007;104(2 Suppl 1):25–8.

    Article  PubMed  Google Scholar 

  37. Montz FJ, Schlaerth JB, Berek JS. Resection of diaphragmatic peritoneum and muscle: role in cytoreductive surgery for ovarian cancer. Gynecol Oncol. 1989;35(3):338–40.

    Article  CAS  PubMed  Google Scholar 

  38. Silver DF. Full-thickness diaphragmatic resection with simple and secure closure to accomplish complete cytoreductive surgery for patients with ovarian cancer. Gynecol Oncol. 2004;95(2):384–7.

    Article  PubMed  Google Scholar 

  39. Cliby W, Dowdy S, Feitoza SS, Gostout BS, Podratz KC. Diaphragm resection for ovarian cancer: technique and short-term complications. Gynecol Oncol. 2004;94(3):655–60.

    Article  PubMed  Google Scholar 

  40. Chereau E, Ballester M, Selle F, Cortez A, Pomel C, Darai E, et al. Pulmonary morbidity of diaphragmatic surgery for stage III/IV ovarian cancer. BJOG. 2009;116(8):1062–8.

    Article  CAS  PubMed  Google Scholar 

  41. Einenkel J, Ott R, Handzel R, Braumann UD, Horn LC. Characteristics and management of diaphragm involvement in patients with primary advanced-stage ovarian, fallopian tube, or peritoneal cancer. Int J Gynecol Cancer. 2009;19(7):1288–97.

    Article  PubMed  Google Scholar 

  42. Eisenhauer EL, D’Angelica MI, Abu-Rustum NR, Sonoda Y, Jarnagin WR, Barakat RR, et al. Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced Mullerian cancer. Gynecol Oncol. 2006;103(3):871–7.

    Article  PubMed  Google Scholar 

  43. Gouy S, Chereau E, Custodio AS, Uzan C, Pautier P, Haie-Meder C, et al. Surgical procedures and morbidities of diaphragmatic surgery in patients undergoing initial or interval debulking surgery for advanced-stage ovarian cancer. J Am Coll Surg. 2010;210(4):509–14.

    Article  PubMed  Google Scholar 

  44. Chereau E, Rouzier R, Gouy S, Ferron G, Narducci F, Bergzoll C, et al. Morbidity of diaphragmatic surgery for advanced ovarian cancer: retrospective study of 148 cases. Eur J Surg Oncol. 2011;37(2):175–80.

    Article  CAS  PubMed  Google Scholar 

  45. Song YJ, Lim MC, Kang S, Seo SS, Kim SH, Han SS, et al. Extended cytoreduction of tumor at the porta hepatis by an interdisciplinary team approach in patients with epithelial ovarian cancer. Gynecol Oncol. 2011;121(2):253–7.

    Article  PubMed  Google Scholar 

  46. Martinez A, Pomel C, Mery E, Querleu D, Gladieff L, Ferron G. Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol. 2011;121(2):258–63.

    Article  CAS  PubMed  Google Scholar 

  47. Sonnendecker EW, Guidozzi F, Margolius KA. Splenectomy during primary maximal cytoreductive surgery for epithelial ovarian cancer. Gynecol Oncol. 1989;35(3):301–6.

    Article  CAS  PubMed  Google Scholar 

  48. Ayhan A, Al RA, Baykal C, Demirtas E, Ayhan A, Yuce K. The influence of splenic metastases on survival in FIGO stage IIIC epithelial ovarian cancer. Int J Gynecol Cancer. 2004;14(1):51–6.

    Article  CAS  PubMed  Google Scholar 

  49. Yildirim Y, Sanci M. The feasibility and morbidity of distal pancreatectomy in extensive cytoreductive surgery for advanced epithelial ovarian cancer. Arch Gynecol Obstet. 2005;272(1):31–4.

    Article  PubMed  Google Scholar 

  50. Eisenkop SM, Spirtos NM, Lin WC. Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer. Gynecol Oncol. 2006;100(2):344–8.

    Article  PubMed  Google Scholar 

  51. Hoffman MS, Tebes SJ, Sayer RA, Lockhart J. Extended cytoreduction of intraabdominal metastatic ovarian cancer in the left upper quadrant utilizing en bloc resection. Am J Obstet Gynecol. 2007;197(2):209 e1–4. discussion 209e.4–5.

    Article  Google Scholar 

  52. Kehoe SM, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, D’Angelica M, Jarnagin WR, et al. Incidence and management of pancreatic leaks after splenectomy with distal pancreatectomy performed during primary cytoreductive surgery for advanced ovarian, peritoneal and fallopian tube cancer. Gynecol Oncol. 2009;112(3):496–500.

    Article  PubMed  Google Scholar 

  53. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26–31.

    Article  PubMed  Google Scholar 

  54. Harter P, Muallem ZM, Buhrmann C, Lorenz D, Kaub C, Hils R, et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol. 2011;121(3):615–9.

    Article  PubMed  Google Scholar 

  55. Bristow RE, Karlan BY, Chi DS, editors. Surgery for ovarian cancer, principles and practice. 2nd ed. New York: Informa Healthcare; 2010.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine, Cincinnati, OH, USA

    Eric L. Eisenhauer MD

  2. Gynecology Service, Pelvic Reconstructive Surgery, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Dennis S. Chi MD

Authors
  1. Eric L. Eisenhauer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dennis S. Chi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric L. Eisenhauer MD .

Editor information

Editors and Affiliations

  1. Urology, University Hospital of North Norway, Tromsø, Norway

    Hitendra R.H. Patel

  2. University College London Hospital, London, United Kingdom

    Tim Mould

  3. Laparoscopic and Robotic Surgery, University of Rochester Medical Center, Rochester, New York, USA

    Jean V. Joseph

  4. Colorectal Surgery, University Hospitals Case Medical Center, Cleveland, Ohio, USA

    Conor P. Delaney

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Eisenhauer, E.L., Chi, D.S. (2015). Extended Surgery for Advanced Ovarian Cancer. In: Patel, H., Mould, T., Joseph, J., Delaney, C. (eds) Pelvic Cancer Surgery. Springer, London. https://doi.org/10.1007/978-1-4471-4258-4_40

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4258-4_40

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4257-7

  • Online ISBN: 978-1-4471-4258-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation